Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, et al. Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol 2025 Jul 21:S2468-1253(25)00129.
PMID: 40706613